Description
In This Episode:
- Richard Pazdur, MD, Director, FDA Oncology Center of Excellence
- Suparna Wedam, MD, Physician, FDA Office of Oncologic Drugs, Division of Oncology 1
- Luke Walker, MD, Global Development Lead, Tucatinib and Vice President, Clinical Development at Seattle Genetics
- Nancy Lin, MD, Associate Chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, Dana-Farber Cancer Institute
- Sandy Weaver, Trial Participant on HER2CLIMB Clinical Trial
- Ulrich Rohr, MD, Deputy Head of Division Clinical Review, SwissMedic
| Name | Financial Relationships | Disclosure Type | Role |
| R. Pazdur | No Relationships | Program Committee, Speaker | |
| S. Wedam | No Relationships | Speaker | |
| L. Walker | Seattle Genetics | Employee | Speaker |
| N. Lin |
Genentech,
Seattle Genetics, AstraZeneca, Merck, Pfizer
|
Consultant,
Grant/research support recipient
|
Speaker |
| S. Weaver | No Relationships | Speaker | |
| U. Rohr | No Relationships | Speaker |
FDA Staff involved in the development and review of this activity have disclosed no relevant financial relationships.
AACR staff involved in the development and review of this activity have disclosed no relevant financial relationships.
Questions About CE?
Please contact the Office of CME at (215) 440-9300 or cme@aacr.org.
TUCATINIB PRESCRIBING INFORMATION